TABLE III.
Series of logistic regression models predicting first-line treatment preference
| Odds Ratio (95% CI) |
|||||||
|---|---|---|---|---|---|---|---|
| Male patient | Female patient | ||||||
| Respondent characteristic | UVB (N=324) |
Etanercept (N=315) |
Adalimumab (N=317) |
Methotrexate (N=313) |
UVB (N=321) |
Etanercept (N=317) |
Adalimumab (N=310) |
| Sex (male) | 1.94* (1.04, 3.62) |
0.39* (0.17, 0.92) |
0.31* (0.12, 0.79) |
1.51 (0.58, 3.94) |
1.94* (1.08, 3.50) |
0.44* (0.20, 0.98) |
0.30* (0.09, 0.95) |
| NPF member | 0.56 (0.31, 1.01) |
0.49 (0.22, 1.10) |
1.62 (0.69, 3.81) |
2.34 (0.99, 5.54) |
n/a | n/a | n/a |
| Region of practice (base: Northeast) | |||||||
| Midwest | 0.85 (0.27, 2.62) |
26.36** (2.88, 241.10) |
0.53 (0.15, 1.94) |
0.55 (0.24, 1.26) |
1.38 (0.47, 4.07) |
19.54** (2.86, 133.57) |
|
| South | n/a | 0.47 (0.18, 1.27) |
16.14* (1.89, 138.14) |
0.74 (0.24, 2.32) |
0.63 (0.30, 1.36) |
1.63 (0.63, 4.23) |
3.94 (0.61, 25.32) |
| West | 0.51 (0.15, 1.79) |
6.57 (0.64, 67.69) |
1.15 (0.34, 3.83) |
0.58 (0.24, 1.40) |
0.67 (0.20, 2.20) |
4.01 (0.53, 30.22) |
|
| Years in practice (base: 0–9 years) | |||||||
| 10–19 years | 0.44 (0.18, 1.06) |
0.95 (0.27, 3.28) |
1.19 (0.37, 3.88) |
2.04 (0.57, 7.26) |
0.96 (0.32, 2.85) |
0.86 (0.20, 3.72) |
|
| 20–29 years | 0.71 (0.31, 1.64) |
1.18 (0.36, 3.88) |
1.33 (0.40, 4.37) |
0.35 (0.08, 1.50) |
n/a | 1.02 (0.35, 2.96) |
1.37 (0.31, 6.13) |
| ≥30 years | 0.70 (0.29, 1.65) |
0.41 (0.10, 1.73) |
0.61 (0.14, 2.61) |
2.26 (0.63, 8.07) |
0.81 (0.24, 2.71) |
0.71 (0.13, 3.95) |
|
| Practice type (base: academic) | |||||||
| Private practice | 0.63 (0.27, 1.49) |
0.93 (0.21, 4.15) |
7.24* (1.08, 48.43) |
0.37 (0.10, 1.36) |
0.46 (0.16, 1.35) |
2.31 (0.57, 9.36) |
4.26 (0.56, 32.45) |
| Multi-specialty, VA, HMO, other | 0.44 (0.15, 1.29) |
1.37 (0.26, 7.12) |
2.03 (0.26, 16.02) |
1.57 (0.41, 5.97) |
0.25* (0.08, 0.78) |
10.17** (1.96, 52.70) |
1.27 (0.15, 10.61) |
| Physician extender hired | n/a | 0.78 (0.33, 1.83) |
1.34 (0.56, 3.21) |
n/a | n/a | n/a | 5.89** (1.95, 17.80) |
| Phototherapy in practice | 3.40*** (1.75, 6.62) |
0.65 (0.27, 1.58) |
n/a | 0.34* (0.14, 0.81) |
2.83** (1.51, 5.29) |
0.48 (0.22, 1.04) |
0.50 (0.17, 1.47) |
| Infusion center affiliation | n/a | 1.30 (0.40, 4.21) |
3.68* (1.04, 13.02) |
0.73 (0.26, 2.04) |
0.79 (0.35, 1.78) |
n/a | 4.92* (1.16, 20.81) |
| Number of psoriasis pts in last 3 | |||||||
| months (base: 1st quartile (0–15)) | |||||||
| 2nd quartile (16–30) | 1.01 (0.36, 2.82) |
2.20 (0.71, 6.84) |
0.80 (0.25, 2.51) |
0.35** (0.16, 0.75) |
2.43 (0.94, 6.27) |
3.80 (0.92, 15.66) |
|
| 3rd quartile (31–60) | n/a | 0.44 (0.13, 1.52) |
1.38 (0.38, 4.99) |
0.90 (0.27, 3.02) |
0.59 (0.26, 1.36) |
0.64 (0.20, 2.02) |
2.76 (0.61, 12.53) |
| 4th quartile (61–999) | 0.39 (0.10, 1.55) |
2.07 (0.52, 8.18) |
0.62 (0.17, 2.30) |
0.29** (0.12, 0.72) |
1.29 (0.40, 4.20) |
2.38 (0.47, 11.95) |
|
| Heavy user of UVB1 | 7.97*** (3.87, 16.42) |
0.22* (0.07, 0.71) |
0.22** (0.07, 0.68) |
0.42 (0.15, 1.20) |
9.59*** (4.25, 21.63) |
0.12*** (0.04, 0.35) |
0.14* (0.03, 0.65) |
| Heavy user of etanercept1 | 0.39* (0.17, 0.89) |
58.56*** (13.35, 256.88) |
0.52 (0.13, 2.12) |
1.50 (0.48, 4.69) |
0.26** (0.11, 0.59) |
31.75*** (9.68, 104.14) |
0.27 (0.06, 1.27) |
| Heavy user of adalimumab1 | 0.54 (0.21, 1.36) |
0.21* (0.05, 0.89) |
3.89 (0.86, 17.65) |
2.05 (0.54, 7.76) |
n/a | 0.35 (0.11, 1.17) |
n/a |
| Heavy user of methotrexate1 | 0.38* (0.16, 0.86) |
0.37 (0.10, 1.40) |
n/a | 5.78*** (2.18, 15.36) |
0.27** (0.12, 0.61) |
0.34* (0.12, 0.98) |
9.55** (2.42, 37.73) |
| Importance of safety | n/a | 0.46* (0.23, 0.91) |
n/a | n/a | n/a | 0.58 (0.31, 1.06) |
n/a |
| Importance of efficacy | n/a | n/a | 2.43* (1.03, 5.71) |
0.58 (0.29, 1.18) |
n/a | n/a | 2.56 (0.96, 6.83) |
| Importance of cost to patient | n/a | 0.70 (0.37, 1.31) |
0.99 (0.53, 1.83) |
1.61 (0.90, 2.89) |
2.12*** (1.39, 3.24) |
0.39** (0.23, 0.67) |
0.32** (0.15, 0.68) |
| Importance of personal experience | n/a | n/a | 1.04 (0.57, 1.87) |
1.05 (0.62, 1.77) |
0.86 (0.60, 1.23) |
n/a | 1.34 (0.70, 2.59) |
| Importance of insurance approval | 0.73 (0.53, 1.01) |
1.54 (0.90, 2.63) |
1.44 (0.87, 2.41) |
0.72 (0.46, 1.12) |
0.73 (0.52, 1.01) |
1.91** (1.23, 2.96) |
1.29 (0.74, 2.26) |
| Importance of ease of administration | 1.30 (0.90, 1.87) |
1.72 (0.99, 2.98) |
0.49* (0.27, 0.88) |
n/a | n/a | n/a | n/a |
*
p<0.05;
**
p<0.01;
***
p<0.001
1
Use of the particular therapy in >10 patients in last 3 months